Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY M WEINBERG

Allopathic & Osteopathic Physicians Dermatology

NPI
1689660565
CMS profile
302744
Location
KEW GARDENS, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$479,656.58

636 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $95,564.33 94
Incyte Corporation $91,887.15 94
E.R. Squibb & Sons, L.L.C. $57,087.65 84
Lilly USA, LLC $46,908.19 43
Dermavant Sciences, Inc. $30,090.42 63
AbbVie Inc. $30,085.98 37
Arcutis Biotherapeutics, Inc. $23,921.80 39
Amgen Inc. $23,067.63 24
Sun Pharmaceutical Industries Inc. $23,051.33 38
GENZYME CORPORATION $18,263.69 16
Regeneron Healthcare Solutions, Inc. $13,987.29 26
UCB, Inc. $13,922.86 22
PFIZER INC. $10,660.67 16
Novartis Pharmaceuticals Corporation $790.94 30
Avita Medical Americas, LLC $125.00 1
Genentech USA, Inc. $84.68 1
Galderma Laboratories, L.P. $52.15 3
LEO Pharma Inc. $50.81 2
Biofrontera Inc. $22.15 1
MAYNE PHARMA COMMERCIAL LLC $16.73 1
Verrica Pharmaceuticals Inc. $15.13 1

Page 2 of 13; records 51–100 of 636 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY M WEINBERG

NPI 1689660565 · CMS profile ID 302744

Allopathic & Osteopathic Physicians / Dermatology

KEW GARDENS, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 13; records 51–100 of 636 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689660565?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY M WEINBERG, NPI 1689660565, CMS profile ID 302744. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 13; records 51–100 of 636 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689660565?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JEFFREY M WEINBERG, NPI 1689660565, CMS profile ID 302744. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 13; records 51–100 of 636 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689660565?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JEFFREY M WEINBERG, NPI 1689660565, CMS profile ID 302744, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 13; records 51–100 of 636 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1689660565?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

636 matching records · $479,656.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 636 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 636.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $664.9411/30/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720515 CMS
Arcutis Biotherapeutics, Inc. $5.0511/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044739329 CMS
Arcutis Biotherapeutics, Inc. $20.4811/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044739355 CMS
AbbVie Inc. $77.1511/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999568613 CMS
Arcutis Biotherapeutics, Inc. $3,375.0011/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044739205 CMS
AbbVie Inc. $4,000.0011/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999568605 CMS
E.R. Squibb & Sons, L.L.C. $3,255.0011/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720487 CMS
E.R. Squibb & Sons, L.L.C. $3,255.0011/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720471 CMS
Novartis Pharmaceuticals Corporation $16.5511/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993357879 CMS
AbbVie Inc. $641.7811/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999568589 CMS
AbbVie Inc. $30.1311/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999568597 CMS
Arcutis Biotherapeutics, Inc. $21.7911/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044739341 CMS
Dermavant Sciences, Inc. $11.1311/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991266509 CMS
Incyte Corporation $2,800.0011/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044335071 CMS
E.R. Squibb & Sons, L.L.C. $0.4611/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720447 CMS
E.R. Squibb & Sons, L.L.C. $2.8511/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720451 CMS
E.R. Squibb & Sons, L.L.C. $0.9311/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720455 CMS
E.R. Squibb & Sons, L.L.C. $4.7311/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720459 CMS
E.R. Squibb & Sons, L.L.C. $4.7211/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720463 CMS
Janssen Biotech, Inc. $4,050.0011/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988455169 CMS
Janssen Biotech, Inc. $39.9011/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988455239 CMS
Janssen Biotech, Inc. $38.2811/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988455249 CMS
Janssen Biotech, Inc. $58.7411/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988455259 CMS
Incyte Corporation $28.0311/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044334993 CMS
Incyte Corporation $58.5011/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044335033 CMS
Incyte Corporation $428.8011/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044335063 CMS
Janssen Biotech, Inc. $315.2711/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988455281 CMS
Janssen Biotech, Inc. $478.4111/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988455291 CMS
Novartis Pharmaceuticals Corporation $22.7611/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993357877 CMS
Sun Pharmaceutical Industries Inc. $2,800.0011/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053868841 CMS
E.R. Squibb & Sons, L.L.C. $124.6611/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720491 CMS
E.R. Squibb & Sons, L.L.C. $912.0411/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720495 CMS
AbbVie Inc. $5.3011/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999568581 CMS
Arcutis Biotherapeutics, Inc. $111.0911/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044739217 CMS
Dermavant Sciences, Inc. $11.6211/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991266505 CMS
E.R. Squibb & Sons, L.L.C. $73.0911/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720377 CMS
E.R. Squibb & Sons, L.L.C. $2,604.0011/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720405 CMS
AbbVie Inc. $18.7811/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999568573 CMS
Janssen Biotech, Inc. $160.7311/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988455179 CMS
Novartis Pharmaceuticals Corporation $7.0611/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993357881 CMS
Sun Pharmaceutical Industries Inc. $1.9411/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053868787 CMS
Sun Pharmaceutical Industries Inc. $6.4711/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053868789 CMS
Janssen Biotech, Inc. $4,050.0011/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988455131 CMS
Amgen Inc. $23.3011/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020597777 CMS
Arcutis Biotherapeutics, Inc. $8.5911/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044739393 CMS
E.R. Squibb & Sons, L.L.C. $766.5511/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720467 CMS
E.R. Squibb & Sons, L.L.C. $119.6711/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015720479 CMS
Janssen Biotech, Inc. $28.4311/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988455367 CMS
Janssen Biotech, Inc. $5.0311/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988455377 CMS
Lilly USA, LLC $17.3911/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031706021 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $358,147.67 561
PY2020 $166,636.41 281
PY2021 $135,158.45 236
PY2022 $318,654.56 448
PY2023 $479,656.58 636
PY2024 $404,048.78 569
PY2025 $401,114.88 541

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $109,079.98 91
PY2024 Principal investigator $443,871.59 192
PY2023 Recipient $3,320.00 1
PY2023 Principal investigator $233,884.17 64
PY2022 Recipient $4,343.59 1
PY2022 Principal investigator $197,932.77 99
PY2021 Recipient $4,687.00 2
PY2021 Principal investigator $315,337.61 108
PY2020 Recipient $35,235.96 20
PY2020 Principal investigator $405,291.02 83
PY2019 Recipient $75,680.51 43
PY2019 Principal investigator $929,893.47 101

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

91 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $19,156.23 12/31/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Multicenter, Blinded, Randomized, Parallel-Group, Comparator-Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid-Face Soft Tissue Augmentation No dispute reported 06/30/2026 1202534887
Principal investigator 1 PFIZER INC. $1,000.00 12/11/2025 Non-covered Recipient Entity
Forest Hills Dermatology Group PLLC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228725150
Principal investigator 1 Incyte Corporation $1,747.80 12/10/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536581
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536586
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536606
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536618
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536654
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536590
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536594
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536598
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536602
Principal investigator 1 Incyte Corporation $12.15 11/05/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536614
Principal investigator 1 Incyte Corporation $80.15 11/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536622
Principal investigator 1 Incyte Corporation $8.48 11/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536625
Principal investigator 1 Incyte Corporation $32.88 11/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536630
Principal investigator 1 Incyte Corporation $32.88 11/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536633
Principal investigator 1 Incyte Corporation $32.88 11/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536637
Principal investigator 1 Incyte Corporation $32.88 11/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536641
Principal investigator 1 Incyte Corporation $49.36 11/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536644
Principal investigator 1 Incyte Corporation $64.72 11/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536658
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,061.29 10/30/2025 Non-covered Recipient Entity
Forest Hills Dermatology Group
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235997289
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,774.90 10/13/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis No dispute reported 06/30/2026 1246432033
Principal investigator 1 Incyte Corporation $1,207.80 10/08/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536610
Principal investigator 1 Incyte Corporation $34.35 10/01/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536574
Principal investigator 1 Incyte Corporation $16.18 10/01/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536578
Principal investigator 1 Incyte Corporation $0.62 10/01/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536650
Principal investigator 1 Incyte Corporation $49.36 10/01/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536663
Principal investigator 1 Incyte Corporation $1,207.80 09/10/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536557
Principal investigator 1 Incyte Corporation $1,207.80 07/09/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536562
Principal investigator 1 UCB SA $5,200.00 07/09/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP PLLC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246657966
Principal investigator 1 Incyte Corporation $4.86 07/01/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536566
Principal investigator 1 Incyte Corporation $32.36 07/01/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536570
Principal investigator 1 Incyte Corporation $1,207.80 06/06/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536489
Principal investigator 1 Incyte Corporation $24.66 06/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536510
Principal investigator 1 Incyte Corporation $12.15 06/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536531
Principal investigator 1 Incyte Corporation $24.66 06/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536544
Principal investigator 1 Incyte Corporation $24.66 06/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536549
Principal investigator 1 Incyte Corporation $24.66 06/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536552
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,929.00 05/16/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis No dispute reported 06/30/2026 1246432029
Principal investigator 1 Incyte Corporation $1,086.70 05/07/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536462
Principal investigator 1 Incyte Corporation $1,481.00 05/07/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536470
Principal investigator 1 SANOFI US SERVICES INC. $11,218.40 05/05/2025 Non-covered Recipient Entity
Forest Hills Dermatology Group Pllc
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226085323
Principal investigator 1 Incyte Corporation $0.93 05/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536501
Principal investigator 1 Incyte Corporation $74.04 05/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536506
Principal investigator 1 Incyte Corporation $22.90 05/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536517
Principal investigator 1 Incyte Corporation $3,541.60 04/18/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240536466
Principal investigator 1 Eli Lilly and Company $13,513.30 04/10/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187881752
Principal investigator 1 Incyte Corporation $1,747.80 04/07/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536522
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,689.80 04/04/2025 Non-covered Recipient Entity
Forest Hills Dermatology Group
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1235997291
Principal investigator 1 Incyte Corporation $280.90 04/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536473
Principal investigator 1 Incyte Corporation $53.80 04/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536478
Principal investigator 1 Incyte Corporation $132.50 04/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536481
Principal investigator 1 Incyte Corporation $37.66 04/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536485
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536493
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536497
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536513
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536526
Principal investigator 1 Incyte Corporation $233.20 04/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536535
Principal investigator 1 Incyte Corporation $12.36 04/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536538
Principal investigator 1 Incyte Corporation $1,430.00 03/12/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536354
Principal investigator 1 Incyte Corporation $1,342.00 03/12/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536361
Principal investigator 1 Incyte Corporation $1,044.90 03/12/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536431
Principal investigator 1 Incyte Corporation $68.70 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536373
Principal investigator 1 Incyte Corporation $24.30 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536376
Principal investigator 1 Incyte Corporation $114.50 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536381
Principal investigator 1 Incyte Corporation $62.27 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536389
Principal investigator 1 Incyte Corporation $135.40 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536393
Principal investigator 1 Incyte Corporation $64.72 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536402
Principal investigator 1 Incyte Corporation $59.13 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536407
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536411
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536415
Principal investigator 1 Incyte Corporation $14.84 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536419
Principal investigator 1 Incyte Corporation $54.76 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536423
Principal investigator 1 Incyte Corporation $80.90 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536427
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536441
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536445
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536450
Principal investigator 1 Incyte Corporation $1,074.20 02/19/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536350
Principal investigator 1 Incyte Corporation $2,128.00 02/19/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536369
Principal investigator 1 Incyte Corporation $1,430.00 01/17/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536341
Principal investigator 1 Incyte Corporation $910.70 01/17/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536346
Principal investigator 1 Incyte Corporation $1,342.00 01/17/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536435
Principal investigator 1 Incyte Corporation $1,342.00 01/17/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536439
Principal investigator 1 PFIZER INC. $1,000.00 01/14/2025 Non-covered Recipient Entity
Forest Hills Dermatology Group PLLC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228799465
Principal investigator 1 Amgen Inc. $9,132.68 01/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
P2 Moderate-Severe pDLE No dispute reported 06/30/2026 1246641466
Principal investigator 1 Incyte Corporation $9.72 01/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536357
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536365
Principal investigator 1 Incyte Corporation $118.26 01/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536386
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536398
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536454
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
FOREST HILLS DERMATOLOGY GROUP
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240536458